Minimal breast cancer: Evaluation of histology and biological marker expression

British Journal of Cancer

Volumn 80, Issue 10, 1999, Pages 1608-1616

  Dublin, E A ^a   Millis, R R ^a   Smith, P ^a   Bobrow, L G ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Differentiation; Marker expression; Minimal breast cancer

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033050947     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690570     Document Type: Article

References (36)

1. Ackerman LV and Katzenstein AL (1977) The concept of minimal breast cancer and the pathologist's role in the diagnosis of 'early carcinoma'. Cancer 39: 2755-2763
2. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilehrist KW, Osborne CK, Tormey DC and McGuire WL (1992) Overexpression of HER-2/neo and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979
3. Arnesson L-G, Smeds S and Fagerberg G (1994) Recurrence-free survival in patients with small breast cancers. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 160: 271-276
4. Barnes DM, Bantkuva J, Camplejohn RS, Gullick WJ, Smith PJ and Millis RR (1992) Overexpression of the c erbB-2 oncoprotein. why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28: 644-648
5. Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-476
6. Barsky SA, Doberneck SA, Sternlicht MD, Grossman DA and Love SM (1997) 'Revetant' DCIS in human axillary breast carcinoma metastases. J Pathol 183: 188-194
7. Bartkova J, Barnes DM and Millis RR (1990) Immunohistochemical demonstration of c erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21: 1164-1167
8. Bellamy COC, McDonald C, Salter DM, Chetty U and Anderson TJ (1993) Non-invasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 24: 16-23
9. Bobrow LG, Happerfield LC, Gregory WM, Springall RG and Millis RR (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11: 215-222
10. Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19: 403-410
11. Gallager HS and Martin JF. (1971) An orientation to the concept of minimal breast cancer. Cancer 28: 1505-1507
12. Goldstein NS and Murphy T (1996) Intraductal carcinoma associated with invasive carcinoma of the breast. Am J Clin Pathol 106: 312-318
13. Harris JR and Schnitt SJ (1990) Is radiotherapy as curative as mastectomy for patients with ductal carcinoma in situ? Int J Radiat Oncol Biol Phys 19: 1091-1092
14. Holland R, Peterse JL, Millis RR, Eusebi V, Faverley D, van de Vijver MJ and Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180
15. Joensuu H and Toikkanen S (1991) Prognosis of breast cancer with small primary tumor (pT1). Acta Oncol 30; 793-796
16. Kapłan EL and Meier P (1958) Non-parametic estimation from incomplete observations. Am Stat Assoc J 53: 457-481
17. Lagios MD, Margolin FR, Westdahl PR and Rose MR (1989) Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63: 618-624
18. Lampejo OT, Barnes DM, Smith P and Millis RR (1994) Evaluation of infiltrating carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 11: 215-222
19. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J. Nicholson R, Cullick WJ, Elston CW and Blamey RW (1991) c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439-143
20. Mack L, Kerkvliet N, Doig G and O'Malley FP (1997) Relanonship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53. c-erbB2, bel 2, and Ki-67. Hum Pathol 28: 974-979
21. Millis RR (1996) Classification of ductal carcinoma in situ of the breast. Adv Anat Pathol 3: 114-129
22. Millis RR, Bubrow LG and Barnes DM (1996) Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: correlation with morphological features and recently proposed schemes for histological classification. Breast 5: 113-122
23. Moriya T and Silverberg SG (1994) Intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 74: 2972-2978
24. Mustafa I. Cole B, Wanebo H, Bland K and Chang H (1998) Prognostic analysis of survival in small breast cancers. J Am Coll Surg 186: 562-56
25. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S. Micklem K, Gelber R, Reed R, Senn HJ, Goldhirsch A and Dyer MJS (1994) Expression of Bcl ·2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5: 409-414
26. Patchefsky AS, Schwartz GF. Finkelstein SD, Prestipino A, Sohn SE, Singer JS and Feig S (1989) Heterogeneity of intraductal carcinoma of the breast. Cancer 63; 731-741
27. Querzoli P, Albunico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, Indelli M and Nenei I (1998) Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer 83: 89-97
28. Rosner D and Lane WW (1990) Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy, Cancer 66: 199-205
29. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL and Harris JR (1988) Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318: 898-903
30. Scott MA, Lagios MD, Axelsson K, Rogers I.W, Anderson T and Page DL (1997) Duclal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 28: 967-973
31. Sinn HP, Oelmann A. Anton HW and Diel IJ (1994) Metastatic potential of small and minimally invasive breast carcinomas. Virchows Arch 425: 237-241.
32. Sobin LH and Wittekind CH (1997) Breast tumours. In: TNM Classification of Tumours, Sobin LH & Wittekind CH (eds). pp. 125-127. Wiley Liss: New York.
33. Tabàr L, Fagerberg G, Day NE, Duffy SW and Kitchin RM (1992) Breast cancer treatment and natural history: new insights from results of screening. Lancet 339; 412-414
34. Tubiana M and Koscielny S (1991) Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 18: 125-140
35. van Dongen J, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR and Recht A (1992) Ductal carcinoma in situ of the breast; second EORTC consensus meeting. Eur J Cancer 28: 626-629
36. Veronese SM and Maisano C (1996) Comparative prognostic value of Ki-67 and MIB-1 proliferate indices in breast cancer. Anticancer Res 16: 2717-2722